{
    "clinical_study": {
        "@rank": "77251", 
        "arm_group": {
            "arm_group_label": "BMN 701", 
            "arm_group_type": "Experimental", 
            "description": "BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks"
        }, 
        "brief_summary": {
            "textblock": "Study 701-301 is a single-arm, open-label, switchover study in patients with late-onset\n      Pompe disease who have been receiving treatment with recombinant human acid\n      alpha-glucosidase (rhGAA) for 48 weeks or longer.  Ambulatory patients who have mild to\n      moderate respiratory impairment will switch directly to receive BMN 701 20mg/kg by IV\n      infusion every other week."
        }, 
        "brief_title": "BMN701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease", 
        "condition": "Late-onset Pompe Disease", 
        "condition_browse": {
            "mesh_term": "Glycogen Storage Disease Type II"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide written informed consent, after the nature of the study\n             has been explained, and prior to any study-related procedures.\n\n          -  Diagnosed with late-onset Pompe disease based on 2 currently or previously documented\n             GAA gene mutations, and endogenous GAA activity <75% of the lower limit of the normal\n             adult range reported by the testing laboratory, as assessed by dried blood spot or\n             whole blood assay.\n\n          -  \u2265 18 years of age at the time of enrollment in the study.\n\n          -  Has received prior treatment with commercial rhGAA as defined by ALL of the\n             following:\n\n          -  has received treatment with commercial rhGAA for \u2265 48 weeks\n\n          -  has received > 80% of all scheduled treatments in the prior 48 weeks and\n\n               -  4 out of the prior 6 scheduled treatments\n\n          -  has received and completed the last two infusions without a drug-related adverse\n             event resulting in dose interruption\n\n          -  has received last treatment of commercial rhGAA \u2265 14 and \u2264 28 days prior to\n             anticipated initiation of treatment with BMN 701\n\n          -  Sexually active subjects must be willing to use two known effective methods of\n             contraception while participating in the study and for at least 4 months following\n             the last dose of BMN 701.\n\n          -  Females of childbearing potential must have a negative pregnancy test at Screening\n             and Baseline visits and be willing to have additional pregnancy tests during the\n             study. Females considered not of childbearing potential include those who have been\n             in menopause at least 2 years, or had tubal ligation at least 1 year prior to\n             Screening, or who have had total hysterectomy.\n\n          -  Has \u2265 30% predicted upright FVC and < 80% predicted upright FVC\n\n          -  Has \u226460% predicted MIP\n\n          -  Must meet ambulation criteria, as measured on two separate days conducted during the\n             Screening and/or Baseline visit (use of assistive devices such as walker, cane, or\n             crutches, is permitted with consistent use throughout the study).\n\n          -  Is willing and able to comply with all study procedures\n\n        Exclusion Criteria:\n\n          -  Use of any investigational product or investigational medical device within 4 weeks\n             prior to Screening, or requirement for any investigational agent other than BMN 701\n             prior to completion of all scheduled study assessments\n\n          -  Received any investigational medication for Pompe disease within the prior 12 months.\n\n          -  Has a diagnosis of diabetes and/or is currently being treated with or anticipated to\n             require treatment with hypoglycemic agents during the course of the study\n\n          -  Has been treated with any immunosuppressive medication other than\n             glucocorticosteroids within the prior 12 months.\n\n          -  Requires noninvasive ventilatory support while awake and in the upright position\n\n          -  Has previously been enrolled to this study\n\n          -  Breastfeeding at Screening or planning to become pregnant (self or partner) at any\n             time during the study.\n\n          -  Concurrent disease, medical condition, or extenuating circumstance that, in the\n             opinion of the Investigator, might compromise subject safety, study treatment\n             compliance and completion of the study, or the integrity of the data collected for\n             the study\n\n          -  Has known hypersensitivity to BMN 701 or its excipients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924845", 
            "org_study_id": "701-301", 
            "secondary_id": "2013-001768-48"
        }, 
        "intervention": {
            "arm_group_label": "BMN 701", 
            "intervention_name": "BMN 701", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mcooley@kumc.edu", 
                    "last_name": "Melissa Cooley", 
                    "phone": "913-945-7697"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "University of Kansas Medical Center"
                }, 
                "investigator": {
                    "last_name": "Richard Barohn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antwerp", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Messina", 
                        "country": "Italy"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salford", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "France", 
                "Italy", 
                "Netherlands", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) in rhGAA Exposed Subjects With Late-onset Pompe Disease", 
        "overall_contact": {
            "email": "cjobson@bmrn.com", 
            "last_name": "Christina Jobson"
        }, 
        "overall_official": {
            "affiliation": "BioMarin Pharmaceutical", 
            "last_name": "William Lang, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: National Health Service", 
                "United Kingdom: Research Ethics Committee", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "percent predicted MIP (Maximum Inspiratory Pressure) measured at the mouth by the Mueller maneuver", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "removed_countries": {
            "country": "Germany"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924845"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "percent predicted MEP (Maximum Expiratory Pressure)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "6 Minute Walk Test", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "BioMarin Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioMarin Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}